An Open-Label Study to Evaluate the Safety and Immunogenicity of 2 Doses of 100µg BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, Given to a Population of Adults in Good General Health Who Have Received 3 Doses of 300µg BG505 SOSIP.GT1.1 gp140 Vaccine, Adjuvanted
Latest Information Update: 23 May 2023
At a glance
- Drugs BG505 SOSIP 664 gp140 adjuvanted vaccine (Primary)
- Indications HIV infections
- Focus Adverse reactions
Most Recent Events
- 23 May 2023 New trial record